NDT Advance Access published online on November 9, 2006
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfl501
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Monash Medical Centre, Nephrology, Melbourne, Victoria, Australia
* To whom correspondence should be addressed.
Letter
Anti CD20 antibody treatment in refractory Class IV Lupus Nephritis
Robert P. Carroll 1 *, Fiona Brown 1, and Peter G. Kerr 1
Robert P. Carroll, E-mail: doctorrobertcarroll{at}yahoo.com
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C. Melander, M. Sallee, P. Trolliet, S. Candon, X. Belenfant, E. Daugas, P. Remy, V. Zarrouk, E. Pillebout, C. Jacquot, et al. Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 579 - 587. [Abstract] [Full Text] [PDF] |
||||
![]() |
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii2 - iii22. [Full Text] [PDF] |
||||
![]() |
B. Ranchin and S. Fargue Review: New treatment strategies for proliferative lupus nephritis: keep children in mind! Lupus, August 1, 2007; 16(8): 684 - 691. [Abstract] [PDF] |
||||


